HAIBIN ZHANG: Open Payments
NPI 1386946481 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$696 in 28 payments from 13 companies in 2025. Trend: 2023 $694 · 2024 $699 · 2025 $696
Food & beverage: $696
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 5 | $144 |
| Astellas Pharma US Inc | 4 | $123 |
| Telix Pharmaceuticals | 4 | $110 |
| ACCORD HEALTHCARE, INC. | 3 | $59 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| UROGEN PHARMA, INC. | 2 | $40 |
| PFIZER INC. | 2 | $38 |
| Novartis Pharmaceuticals Corporation | 1 | $31 |
| IMMUNITYBIO, INC. | 1 | $28 |
| Tempus AI, Inc | 1 | $27 |
Products named: ERLEADA, Xtandi, ILLUCCIX, Camcevi, GEMTESA, PLUVICTO, Padcev, ANKTIVA.
Industry payments across NV — which companies pay providers there.
